CORT
A courtroom sequel nobody asked for
Corcept Therapeutics is back in the spotlight, but not for a biotech victory lap. A shareholder rights firm is pushing investors toward a securities class action tied to the company’s relacorilant story, with a lead-plaintiff deadline set for April 21.
The FDA plot twist
Here’s the heart of the complaint: investors say Corcept painted a rosy picture of relacorilant while allegedly keeping quiet about warning signs from the FDA. According to the notice, the agency had been telling the company in pre-submission meetings that the clinical data didn’t show enough evidence of effectiveness.
Then came the CRL hammer
On December 31, 2025, Corcept disclosed a Complete Response Letter from the FDA. That’s the biotech equivalent of getting your movie greenlit... and then the studio walks in and says, "Actually, never mind." The stock promptly cratered, falling from $70.20 to $34.80 in a single day and wiping out roughly $2.5 billion in market value.
Why investors should care
This isn’t just legal paperwork. Securities cases can drag on for months, sometimes years, and they can keep a fresh cloud over a stock that’s already dealing with a regulatory gut punch. If you own CORT, the key question is whether this becomes a long, noisy distraction or another reminder that FDA risk can turn a biotech thesis into confetti fast.
Big picture: when a drug story runs into an FDA wall, the science gets messy — and the lawsuits usually show up right on cue.